Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

enthalten in: Pneumologie | 2017

von Schütte, W. | Barlesi, F. | Park, K. | +17